Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:MORNASDAQ:MRUSNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$40.99+3.5%$42.41$17.86▼$58.40$3.26B-0.18861,680 shs1.87 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMRUSMerus$44.36+6.0%$43.97$33.19▼$61.61$3.06B1.02718,875 shs1.00 million shsVIRVir Biotechnology$6.29+5.4%$6.97$4.95▼$14.45$862.63M1.141.34 million shs1.00 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+3.39%+8.93%-9.39%+56.57%+102.32%MORMorphoSys0.00%0.00%0.00%0.00%+5.04%MRUSMerus+6.05%+3.02%-5.58%+7.41%+5.69%VIRVir Biotechnology+5.36%+14.36%-9.50%-40.83%-21.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics4.1786 of 5 stars4.52.00.04.72.21.70.0MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AMRUSMerus3.1559 of 5 stars4.62.00.00.04.11.70.0VIRVir Biotechnology2.7589 of 5 stars3.41.00.00.02.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$76.2986.11% UpsideMORMorphoSys 0.00N/AN/AN/AMRUSMerus 3.13Buy$85.3192.31% UpsideVIRVir Biotechnology 2.86Moderate Buy$33.57433.73% UpsideCurrent Analyst Ratings BreakdownLatest VIR, AKRO, MRUS, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/18/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/10/2025MRUSMerusBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.003/3/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $75.003/3/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.003/2/2025AKROAkero TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight2/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$85.00 ➝ $83.002/28/2025VIRVir BiotechnologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $31.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17MRUSMerus$36.13M84.82N/AN/A$6.17 per share7.19VIRVir Biotechnology$63.71M13.54N/AN/A$11.82 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$151.76M-$3.75N/AN/AN/AN/A-32.46%-29.83%5/9/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AMRUSMerus-$154.94M-$3.27N/AN/AN/A-680.61%-38.89%-31.16%5/6/2025 (Estimated)VIRVir Biotechnology-$615.06M-$3.82N/AN/AN/A-678.40%-36.71%-31.00%5/1/2025 (Estimated)Latest VIR, AKRO, MRUS, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17N/AN/AN/AN/AN/A5/9/2025Q1 2025AKROAkero Therapeutics-$1.00N/AN/AN/AN/AN/A5/1/2025Q1 2025VIRVir Biotechnology-$0.83N/AN/AN/A$8.59 millionN/A2/28/2025Q4 2024AKROAkero Therapeutics-$0.98-$0.99-$0.01-$0.99N/AN/A2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 million2/26/2025Q4 2024VIRVir Biotechnology-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0517.2517.25MORMorphoSys4.981.381.38MRUSMerusN/A8.328.32VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AMORMorphoSys18.38%MRUSMerus96.14%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.94%MORMorphoSys0.05%MRUSMerus4.57%VIRVir Biotechnology15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.62 million64.26 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableMRUSMerus3769.09 million65.34 millionOptionableVIRVir Biotechnology580137.14 million116.24 millionOptionableVIR, AKRO, MRUS, and MOR HeadlinesRecent News About These CompaniesVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by AnalystsApril 25 at 6:23 AM | marketbeat.comVir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025April 24 at 10:08 AM | businesswire.comVir Biotechnology (VIR) to Release Quarterly Earnings on ThursdayApril 24 at 3:47 AM | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Shares Up 5.5% - Here's What HappenedApril 23 at 1:58 PM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Up 28.3% in MarchApril 21, 2025 | marketbeat.comWalleye Capital LLC Increases Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)April 20, 2025 | marketbeat.comRenaissance Technologies LLC Buys 55,300 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)April 20, 2025 | marketbeat.comQuinn Opportunity Partners LLC Purchases Shares of 65,976 Vir Biotechnology, Inc. (NASDAQ:VIR)April 14, 2025 | marketbeat.comNew Mpro inhibitors revealed in Vir Biotechnology patentApril 11, 2025 | bioworld.comExodusPoint Capital Management LP Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)April 11, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Here's WhyApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Sells 255,118 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)April 9, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in StockApril 6, 2025 | marketbeat.comPrudential Financial Inc. Sells 180,800 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)April 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's What HappenedApril 2, 2025 | marketbeat.comStock Movers: Moderna, Tesla, Canada GooseMarch 31, 2025 | bloomberg.comWINTON GROUP Ltd Sells 38,730 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)March 31, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from AnalystsMarch 30, 2025 | marketbeat.comArtisan Partners Limited Partnership Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)March 30, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the companyMarch 28, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines4 Healthcare Stocks With Massive Gains—and More to ComeBy Sarah Horvath | March 29, 2025View 4 Healthcare Stocks With Massive Gains—and More to ComeD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyCrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsBy Chris Markoch | April 15, 2025View CrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsIs Alphabet a Generational Buying Opportunity at These Levels?By Ryan Hasson | April 9, 2025View Is Alphabet a Generational Buying Opportunity at These Levels?Medtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and InnovationVIR, AKRO, MRUS, and MOR Company DescriptionsAkero Therapeutics NASDAQ:AKRO$40.99 +1.38 (+3.48%) Closing price 04/24/2025 04:00 PM EasternExtended Trading$41.60 +0.61 (+1.49%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 04/23/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Merus NASDAQ:MRUS$44.36 +2.53 (+6.05%) Closing price 04/24/2025 04:00 PM EasternExtended Trading$43.59 -0.77 (-1.74%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Vir Biotechnology NASDAQ:VIR$6.29 +0.32 (+5.36%) Closing price 04/24/2025 04:00 PM EasternExtended Trading$6.36 +0.07 (+1.03%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
